Robin Choudhury

BACKGROUND:

Robin Choudhury qualified in medicine at the University of Oxford with postgraduate training in London (Royal Brompton & Hammersmith) and at Mount Sinai School of Medicine, New York.  He is Professor of Cardiovascular Medicine at the University of Oxford; Consultant Cardiologist to the John Radcliffe Hospital and Research Fellow in Biomedical Sciences at Balliol.  He is an Affiliated Researcher at the Institute of Regenerative Medicine.

He is co-PI of of the NovoNordisk Foundation supported Metabolite-related inflammation and disease (MeRIAD) consortium; Joint clinical lead in the MRC-BHF Centre of Research Excellence in Advanced Cardiac Therapies (REACT) and UK Chief Investigator for the ZEUS clinical trial of Ziltivekimab.

RESEARCH:

His translational science laboratory aims to understand how cells of the innate immune system are involved in processes of tissue homeostasis, injury and repair.

Areas of particular interest focus around: (1) understanding the role of monocytes, macrophages and neutrophils in acute myocardial infarction; myocardial regeneration vs repair and in atherosclerosis and (2) how bone marrow stem cells are 'programmed' e.g. by extracellular vesicles and through by genetic / epigenetic and metabolic mechanisms.  The laboratory has a particular interest in hyperglycaemia-induced trained immunity.

CLINICAL PRACTICE:

Professor Choudhury has a specialist clinical interest in coronary artery disease and its management. He has  particular expertise in the assessment and optimisation of cardiovascular risk factors and their interactions  (e.g. cholesterol; diabetes; 'inflammation' and genetic risk).